Several major pharmaceutical companies, including Pfizer, Amgen, Sanofi, and AstraZeneca, are leading the market for dyslipidemia treatments.
1 report, 1 independent
Updated Aug 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Several major pharmaceutical companies, including Pfizer, Amgen, Sanofi, and AstraZeneca, are leading the market for dyslipidemia treatments.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Arrowhead Pharmaceuticals and Amgen are developing RNAi-based therapies for dyslipidemias.Sub-event
Major pharma companies are leading the dyslipidemia treatment market as of August 2025.1 source
Keep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Amgen
American multinational biopharmaceutical company
-
Sanofi
company in Milan, Italy
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireDyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic Dyslipidem